FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229444744> ?p ?o ?g. }

• W4229444744 endingPage "3920" @default.
• W4229444744 startingPage "3911" @default.
• W4229444744 abstract "This phase 1 study evaluated safety, tolerability, and preliminary efficacy of obinutuzumab in combination with venetoclax in patients with previously untreated grade 1-3a follicular lymphoma in need of systemic therapy. Two DLs of venetoclax were evaluated with an expansion cohort at the recommended phase 2 dose. Twenty-five patients were enrolled. The recommended phase 2 dose was venetoclax 800 mg OD continuously for 6 cycles starting on day 2 of cycle 1, with obinutuzumab 1000 mg on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2 to 6, followed by obinutuzumab maintenance every 2 months for 2 years. Only 1 patient had a DLT consisting of grade 4 thrombocytopenia after the first obinutuzumab infusion. Neutropenia was the most common adverse event of grade ≥3 at least possibly attributed to study treatment. Twenty-four patients were evaluable for response after cycle 6 by computed tomography (CT) and 19 by positron emission tomography/CT (PET/CT): overall and complete response rates were 87.5% (95% CI, 67.6% to 97.3%) and 25% (95% CI, 9.8% to 46.7%) in the CT-evaluated patients and 84.2% (95% CI, 60.4% to 96.6%) and 68.4% (95% CI, 43.4% to 87.4%), respectively, in the PET/CT-evaluated patients. One-year progression-free survival was 77.8% (95% CI, 54.6% to 90.1%) and 79% (95% CI, 47.9% to 92.7%) for CT and PET/CT-evaluable patients, respectively, whereas progression-free survival at 30 months was 73.2% (95% CI, 49.8%, 87.0%) as assessed by CT and 79.0% (95% CI, 47.9%, 92.7%) by PET/CT. Despite the activity observed, our results do not support further development of the combination in this patient population. This trial was registered at www.clinicaltrials.gov as #NCT02877550." @default.
• W4229444744 created "2022-05-11" @default.
• W4229444744 creator A5009234092 @default.
• W4229444744 creator A5015790909 @default.
• W4229444744 creator A5015825771 @default.
• W4229444744 creator A5016787940 @default.
• W4229444744 creator A5020235177 @default.
• W4229444744 creator A5021191432 @default.
• W4229444744 creator A5022277766 @default.
• W4229444744 creator A5027857526 @default.
• W4229444744 creator A5032114353 @default.
• W4229444744 creator A5033935778 @default.
• W4229444744 creator A5035277761 @default.
• W4229444744 creator A5041567047 @default.
• W4229444744 creator A5044479977 @default.
• W4229444744 creator A5045139107 @default.
• W4229444744 creator A5047236032 @default.
• W4229444744 creator A5048622832 @default.
• W4229444744 creator A5050974067 @default.
• W4229444744 creator A5065286411 @default.
• W4229444744 creator A5066518317 @default.
• W4229444744 creator A5071347282 @default.
• W4229444744 creator A5073165908 @default.
• W4229444744 creator A5075117420 @default.
• W4229444744 creator A5088718388 @default.
• W4229444744 creator A5090442302 @default.
• W4229444744 creator A5091441095 @default.
• W4229444744 date "2022-07-06" @default.
• W4229444744 modified "2023-10-16" @default.
• W4229444744 title "SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma" @default.
• W4229444744 cites W2020094108 @default.
• W4229444744 cites W2029002386 @default.
• W4229444744 cites W2085346499 @default.
• W4229444744 cites W2101648653 @default.
• W4229444744 cites W2115499099 @default.
• W4229444744 cites W2119147717 @default.
• W4229444744 cites W2131900456 @default.
• W4229444744 cites W2163450464 @default.
• W4229444744 cites W2169209759 @default.
• W4229444744 cites W2192121806 @default.
• W4229444744 cites W2335468012 @default.
• W4229444744 cites W2582696216 @default.
• W4229444744 cites W2598700764 @default.
• W4229444744 cites W2606858147 @default.
• W4229444744 cites W2729141564 @default.
• W4229444744 cites W2761234508 @default.
• W4229444744 cites W2761878534 @default.
• W4229444744 cites W2765414225 @default.
• W4229444744 cites W2792666902 @default.
• W4229444744 cites W2795301499 @default.
• W4229444744 cites W2805989660 @default.
• W4229444744 cites W2883570202 @default.
• W4229444744 cites W2891543930 @default.
• W4229444744 cites W2906575149 @default.
• W4229444744 cites W2922237910 @default.
• W4229444744 cites W2922692686 @default.
• W4229444744 cites W2945280131 @default.
• W4229444744 cites W2955463869 @default.
• W4229444744 cites W2963759094 @default.
• W4229444744 cites W3003344682 @default.
• W4229444744 cites W3043558719 @default.
• W4229444744 cites W3068023701 @default.
• W4229444744 cites W3164555487 @default.
• W4229444744 doi "https://doi.org/10.1182/bloodadvances.2021006520" @default.
• W4229444744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35537101" @default.
• W4229444744 hasPublicationYear "2022" @default.
• W4229444744 type Work @default.
• W4229444744 citedByCount "3" @default.
• W4229444744 countsByYear W42294447442022 @default.
• W4229444744 countsByYear W42294447442023 @default.
• W4229444744 crossrefType "journal-article" @default.
• W4229444744 hasAuthorship W4229444744A5009234092 @default.
• W4229444744 hasAuthorship W4229444744A5015790909 @default.
• W4229444744 hasAuthorship W4229444744A5015825771 @default.
• W4229444744 hasAuthorship W4229444744A5016787940 @default.
• W4229444744 hasAuthorship W4229444744A5020235177 @default.
• W4229444744 hasAuthorship W4229444744A5021191432 @default.
• W4229444744 hasAuthorship W4229444744A5022277766 @default.
• W4229444744 hasAuthorship W4229444744A5027857526 @default.
• W4229444744 hasAuthorship W4229444744A5032114353 @default.
• W4229444744 hasAuthorship W4229444744A5033935778 @default.
• W4229444744 hasAuthorship W4229444744A5035277761 @default.
• W4229444744 hasAuthorship W4229444744A5041567047 @default.
• W4229444744 hasAuthorship W4229444744A5044479977 @default.
• W4229444744 hasAuthorship W4229444744A5045139107 @default.
• W4229444744 hasAuthorship W4229444744A5047236032 @default.
• W4229444744 hasAuthorship W4229444744A5048622832 @default.
• W4229444744 hasAuthorship W4229444744A5050974067 @default.
• W4229444744 hasAuthorship W4229444744A5065286411 @default.
• W4229444744 hasAuthorship W4229444744A5066518317 @default.
• W4229444744 hasAuthorship W4229444744A5071347282 @default.
• W4229444744 hasAuthorship W4229444744A5073165908 @default.
• W4229444744 hasAuthorship W4229444744A5075117420 @default.
• W4229444744 hasAuthorship W4229444744A5088718388 @default.
• W4229444744 hasAuthorship W4229444744A5090442302 @default.
• W4229444744 hasAuthorship W4229444744A5091441095 @default.
• W4229444744 hasConcept C126322002 @default.
• W4229444744 hasConcept C197934379 @default.

• next